ImmuCell Corp. (ICCC)
9.75
+0.15
(+1.56%)
USD |
NASDAQ |
Oct 02, 16:00
ImmuCell Shareholders Equity (Quarterly) : 31.37M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.37M |
| March 31, 2026 | 29.14M |
| December 31, 2025 | 27.06M |
| September 30, 2025 | 29.80M |
| June 30, 2025 | 29.87M |
| March 31, 2025 | 28.99M |
| December 31, 2024 | 27.52M |
| September 30, 2024 | 26.41M |
| June 30, 2024 | 23.46M |
| March 31, 2024 | 24.64M |
| December 31, 2023 | 24.99M |
| September 30, 2023 | 26.01M |
| June 30, 2023 | 26.86M |
| March 31, 2023 | 28.16M |
| December 31, 2022 | 30.38M |
| September 30, 2022 | 31.98M |
| June 30, 2022 | 32.55M |
| March 31, 2022 | 33.37M |
| December 31, 2021 | 32.58M |
| September 30, 2021 | 32.46M |
| June 30, 2021 | 32.27M |
| March 31, 2021 | 27.87M |
| December 31, 2020 | 28.27M |
| September 30, 2020 | 28.02M |
| June 30, 2020 | 28.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 28.99M |
| December 31, 2019 | 28.99M |
| September 30, 2019 | 29.19M |
| June 30, 2019 | 29.64M |
| March 31, 2019 | 30.25M |
| December 31, 2018 | 21.74M |
| September 30, 2018 | 22.67M |
| June 30, 2018 | 22.81M |
| March 31, 2018 | 23.49M |
| December 31, 2017 | 23.59M |
| September 30, 2017 | 20.95M |
| June 30, 2017 | 20.20M |
| March 31, 2017 | 20.37M |
| December 31, 2016 | 19.72M |
| September 30, 2016 | 16.41M |
| June 30, 2016 | 16.31M |
| March 31, 2016 | 16.32M |
| December 31, 2015 | 10.61M |
| September 30, 2015 | 10.30M |
| June 30, 2015 | 9.904M |
| March 31, 2015 | 9.743M |
| December 31, 2014 | 9.258M |
| September 30, 2014 | 9.124M |
| June 30, 2014 | 9.103M |
| March 31, 2014 | 9.392M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
| Biogen, Inc. | 18.85B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 46.63M |
| Total Liabilities (Quarterly) | 15.26M |
| Debt to Equity Ratio | 0.3967 |
| Current Ratio | 4.752 |
| Net Debt Paydown Yield | 0.48% |